Publikationen, an denen er mitarbeitet Ángel Carracedo Álvarez (37)

2024

  1. An Insertion Within SIRPβ1 Shows a Dual Effect Over Alzheimer's Disease Cognitive Decline Altering the Microglial Response

    Journal of Alzheimer's Disease, Vol. 98, Núm. 2, pp. 601-618

  2. Clustering Schizophrenia Genes by Their Temporal Expression Patterns Aids Functional Interpretation

    Schizophrenia Bulletin, Vol. 50, Núm. 2, pp. 327-338

2023

  1. A second update on mapping the human genetic architecture of COVID-19

    Nature

  2. Differences in Patterns of Stimulant Use and Their Impact on First-Episode Psychosis Incidence: An Analysis of the EUGEI Study

    Schizophrenia Bulletin, Vol. 49, Núm. 5, pp. 1269-1280

  3. Erratum: Author Correction: Common variants in Alzheimer's disease and risk stratification by polygenic risk scores (Nature communications (2021) 12 1 (3417))

    Nature communications

  4. Examining the association between exposome score for schizophrenia and cognition in schizophrenia, siblings, and healthy controls: Results from the EUGEI study

    Psychiatry Research, Vol. 323

  5. Mendelian Randomisation Confirms the Role of Y-Chromosome Loss in Alzheimer’s Disease Aetiopathogenesis in Men

    International Journal of Molecular Sciences, Vol. 24, Núm. 2

  6. The relationship between genetic liability, childhood maltreatment, and IQ: findings from the EU-GEI multicentric case–control study

    Social Psychiatry and Psychiatric Epidemiology, Vol. 58, Núm. 10, pp. 1573-1580

2022

  1. A replication study of JTC bias, genetic liability for psychosis and delusional ideation

    Psychological Medicine, Vol. 52, Núm. 9, pp. 1777-1783

  2. Evidence, and replication thereof, that molecular-genetic and environmental risks for psychosis impact through an affective pathway

    Psychological Medicine, Vol. 52, Núm. 10, pp. 1910-1922

  3. Examining facial emotion recognition as an intermediate phenotype for psychosis: Findings from the EUGEI study

    Progress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 113

  4. New insights into the genetic etiology of Alzheimer's disease and related dementias

    Nature genetics, Vol. 54, Núm. 4, pp. 412-436

  5. The association between cannabis use and facial emotion recognition in schizophrenia, siblings, and healthy controls: Results from the EUGEI study

    European Neuropsychopharmacology, Vol. 63, pp. 47-59

2021

  1. Cognitive functioning throughout adulthood and illness stages in individuals with psychotic disorders and their unaffected siblings

    Molecular Psychiatry, Vol. 26, Núm. 8, pp. 4529-4543

  2. Common variants in Alzheimer's disease and risk stratification by polygenic risk scores

    Nature communications, Vol. 12, Núm. 1, pp. 3417

  3. Examining the association between exposome score for schizophrenia and functioning in schizophrenia, siblings, and healthy controls: Results from the EUGEI study

    European psychiatry : the journal of the Association of European Psychiatrists, Vol. 64, Núm. 1, pp. e25

  4. Genomic characterization of host factors related to SARS-CoV-2 infection in people with dementia and control populations: The GR@ACE/DEGESCO study

    Journal of Personalized Medicine, Vol. 11, Núm. 12

  5. Long runs of homozygosity are associated with Alzheimer’s disease

    Translational Psychiatry, Vol. 11, Núm. 1

  6. The continuity of effect of schizophrenia polygenic risk score and patterns of cannabis use on transdiagnostic symptom dimensions at first-episode psychosis: findings from the EU-GEI study

    Translational Psychiatry, Vol. 11, Núm. 1

2020

  1. Examining the independent and joint effects of genomic and exposomic liabilities for schizophrenia across the psychosis spectrum

    Epidemiology and Psychiatric Sciences